
#788236: The PREDICT Registry: A prospective registry study to evaluate the effect of the DCISionRT test on treatment decisions in patients with DCIS following breast conserving therapy PRELUDEX

¹PreludeDx, Laguna Hills, CA, ²Nashville Breast Center, Nashville, TN, ³Good Samaritan Cancer Center, Los Gatos, CA, ⁴University of South Florida, Tampa, FL, USA

	Protocol Synopsis		Protocol Synopsis, continued
Brief Title Official Title	NCT03448926 The PREDICT Registry A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy	Cohorts	before and after availability of the genomic test (DCISionBT) results. The
Brief Summary	This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de- identified database of patients, test results, treatment decisions and outcomes that can be queried to determine the utility of the DCISionRT test in the diagnosis and treatment of ductal carcinoma in situ of the breast.		data elements include type of surgery (lumpectomy, therapeutic mastectomy, contralateral prophylactic mastectomy), type of radiation therapy (none, IORT, APBI, whole breast RT) and endocrine therapy (yes, no). The main measure will be percent of cases in which treatment recommendations are changed after the test results become available.
	spective Observational Cohort [Patient Registry] gnostic Test: DCISionRT - The DCISionRT Test was developed by ludeDx (Laguna Hills, CA) and is performed at its CLIA laboratory facility. biomarkers used to evaluate the biologic signature of DCIS tissue are sed on over a decade of research including the University of California, San ncisco, Yale University as well as Prelude Corporation. The test is gnostic for 10-year recurrence risk and predicts RT treatment benefit for asive breast cancer. The laboratory is regulated under the Clinical poratory Improvement Amendments of 1988 (CLIA) as qualified to perform	Secondary Outcome Measures	 DCISionRT results are known as a function of demographic factors (age groups <40, 40-50 and >50; ethnicity; family history) Function of Tumor Factors [Time Frame: 5 years] Percent of patients for which the recommended treatments change after DCISionRT results are known as a function of tumor factors (tumor size, grade, architecture, necrosis, palpability, surgical margins, hormone receptor status).
	high-complexity clinical testing and is accredited by the College of American Pathologists (CAP). The study population will be selected from the clinical practices of the participating investigators and institutions. Patients who have been recently diagnosed with DCIS and are being evaluated for the need for further therapy will be screened for eligibility per the following eligibility criteria.	Other Pre- specified Outcome Measures	Risk Score (0 - 10.0), Risk Category Low (≤3.0) or Elevated (>3.0), Risk Prognosis with Breast Conserving Therapy Alone (0 - 40%) and Risk Prognosis with Breast Conserving Therapy and Radiation (0 - 40%) Function of Geographic Region [Time Frame: 5 years] Percent of patients for which the recommended treatments change after DCISionRT results are known as a function of the geographic region of
Criteria	 Inclusion criteria: Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable) Patient must have the DCISionRT Test ordered during routine patient care Patient must be planning to undergo breast conserving surgery Patient must be eligible to receive radiation and/or systemic treatment Patient must have been diagnosed with DCIS within 120 days of consent Patient must be able to provide informed consent 	Enrollment Target Start Date Est. Completion	
	 Exclusion criteria: Patient tissue is insufficient to generate DCISionRT test results or required DCISionRT inputs (age, tumor size, margin status, palpability) are missing Patient has evidence of invasive breast cancer, including microinvasion, lymph node involvement, or Paget's disease of the nipple or suspicious mammogram findings in the lymph nodes or contralateral breast Patient has been surgically treated with a mastectomy for primary DCIS Patient has prior in situ or invasive breast cancer Patient is pregnant 	Party Study Sponsor Lead Investigators	University of South Florida PreludeDx Charles E Cox, MD University of South Florida Tampa, FL Rakesh R Patel, MD Good Samaritan Hospital Los Gatos, CA Pat Whitworth, MD Nashville Breast Center Nashville, TN Bremer T, et. al, Clin Cancer Res 2018 Dec 1;24(23):5895-5901. PMID: <u>30054280</u> Weinmann S, et al, Clin Cancer Res 2020 Apr 27. PMID: <u>32341032</u> Warnberg F, et. al, SABCS 2017, GS5-08 Whitworth P, et. al, SABCS 2016, S5-01

SC Shivers¹, P Whitworth², R Patel³, T Bremer¹, CE Cox⁴



Study has consented 914 women with 458 consented in 2019.

- ites registered and an additional 20 sites are pending activation.
- EDICT is to activate up to 100 sites and consent 2,500 patients diagnosed with DCIS.
- the study is to evaluate the percent of cases in which treatment recommendations are changed after the results become available.
- Study will have 5 and 10 year follow up.





